GLUT-1 expression in pancreatic neoplasia: Implications in pathogenesis, diagnosis, and prognosis

Pancreas

Volumn 40, Issue 2, 2011, Pages 187-192

  Basturk, Olca ^a   Singh, Rajendra ^b   Kaygusuz, Ecmel ^c   Balci, Serdar ^d   Dursun, Nevra ^d   Culhaci, Nil ^e   Adsay, N Volkan ^d  

^a NEW YORK UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c Zeynep Kamil Hospital   (Turkey)

^d EMORY UNIVERSITY HOSPITAL   (United States)

^e ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

clear cell; GLUT 1; HIF 1 ; mucinous; pancreas; serous

Indexed keywords

GLUCOSE TRANSPORTER 1;

ANTIBODY LABELING; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYSTADENOMA; DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LYMPH NODE; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PANCREATIC INTRAEPITHELIAL NEOPLASM; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; CHI-SQUARE DISTRIBUTION; CYSTADENOMA, SEROUS; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TURKEY; UNITED STATES; UP-REGULATION;

EID: 79951725344     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318201c935     Document Type: Article

References (44)

1. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202(3):654-662. (Pubitemid 40175840)
2. Cornford EM, Hyman S, Swartz BE. The human brain GLUT1 glucose transporter: ultrastructural localization to the blood-brain barrier endothelia. J Cereb Blood Flow Metab. 1994;14(1):106-112.
3. Kayano T, Burant CF, Fukumoto H, et al. Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6). J Biol Chem. 1990;265(22):13276-13282.
4. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20(2):215-220. (Pubitemid 46422176)
5. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92(3): 634-641. (Pubitemid 32735200)
6. Noguchi Y, Marat D, Saito A, et al. Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology. 1999;46(28):2683-2689. (Pubitemid 29454167)
7. Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170(1):223-230. (Pubitemid 20249408)
8. Younes M, Brown RW, Mody DR, et al. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995;15(6B):2895-2898. (Pubitemid 26095119)
9. Younes M, Brown RW, Stephenson M, et al. Overexpression of GLUT1 and GLUT3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80(6):1046-1051. (Pubitemid 27427603)
10. Younes M, Juarez D, Lechago LV, et al. GLUT 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001;21(1B):575-578. (Pubitemid 32267574)
11. Ito H, Duxbury M, Zinner MJ, et al. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery. 2004;136(3):548-556. (Pubitemid 39186566)
12. Edge SB, Byrid DR, Compton CC, et al, eds. AJCC Cancer Staging Handbook. 7th ed. New York: Springer New York, Inc; 2010:241-242.
13. Adsay NV, Basturk O, Bonnett M, et al. A proposal for a new and more practical grading scheme for pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2005;29(6):724-733. (Pubitemid 40734422)
14. Reisser C, Eichhorn K, Herold-Mende C, et al. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer. 1999;80(2): 194-198. (Pubitemid 29001721)
15. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83(1):34-40. (Pubitemid 28299626)
16. Lidgren A, Bergh A, Grankvist K, et al. Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 α. BJU Int. 2008;101(4):480-484. (Pubitemid 351160927)
17. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 2007;53(4):233-256. (Pubitemid 47074647)
18. Ozbudak IH, Shilo K, Tavora F, et al. Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. Mod Pathol. 2009;22(5):633-638.
19. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43(2):173-180.
20. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38(9): 1337-1344. (Pubitemid 27386185)
21. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998;39(10):1727-1735. (Pubitemid 28473521)
22. Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med. 1997;38(9):1344-1348.
23. Sperti C, Bissoli S, Pasquali C, et al. 18-Fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2007;246(6):932-937. (Pubitemid 350179174)
24. 18F-FDG PET findings and GLUT-1 expression in IPMNs of the pancreas. J Nucl Med. 2008;49(12):2070.
25. Sperti C, Pasquali C, Chierichetti F, et al. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg. 2003;7(8):953-959.
26. Nakata B, Chung YS, Nishimura S, et al. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer. 1997;79(4):695-699. (Pubitemid 27076335)
27. Sperti C, Pasquali C, Decet G, et al. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg. 2005;9(1):22-28.
28. Pizzi S, Porzionato A, Pasquali C, et al. Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol Histopathol. 2009;24(2):175-185.
29. Sun HC, Qiu ZJ, Liu J, et al. Expression of hypoxia-inducible factor-1 α and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol. 2007;30(6):1359-1367.
30. Lyshchik A, Higashi T, Hara T, et al. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest. 2007;25(3): 154-162. (Pubitemid 47164858)
31. Ujiki MB, Ding XZ, Salabat MR, et al. Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol Cancer. 2006;5:76.
32. Melstrom LG, Salabat MR, Ding XZ, et al. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008;37(4): 426-431.
33. Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235(4795):1492-1495. (Pubitemid 17038084)
34. Chen C, Pore N, Behrooz A, et al. Regulation of GLUT1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 2001;276(12):9519-9525.
35. Fleming JB, Shen GL, Holloway SE, et al. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res. 2005;3(7):413-423. (Pubitemid 41045591)
36. Moore PS, Beghelli S, Zamboni G, et al. Genetic abnormalities in pancreatic cancer. Mol Cancer. 2003;2:7.
37. Adsay NV, Basturk O, Cheng JD, et al. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol. 2005;15(4):254-264. (Pubitemid 41377141)
38. Thirabanjasak D, Basturk O, Altinel D, et al. Is serous cystadenoma of the pancreas a model of clear-cell-associated angiogenesis and tumorigenesis? Pancreatology. 2009;9(1-2):182-188.
39. Gong K, Zhang N, Na X, et al. The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene. Zhonghua Wai Ke Za Zhi [in Chinese]. 2005;43(6):390-393.
40. Paltoglou SM, Roberts BJ. Role of the von Hippel-Lindau tumour suppressor protein in the regulation of HIF-1alpha and its oxygen-regulated transactivation domains at high cell density. Oncogene. 2005;24(23):3830-3835. (Pubitemid 40826881)
41. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein vHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271-275. (Pubitemid 29246458)
42. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev. 2001;11(3):293-299. (Pubitemid 32480296)
43. Akakura N, Kobayashi M, Horiuchi I, et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001;61(17):6548-6554. (Pubitemid 32783263)
44. Ding XZ, Fehsenfeld DM, Murphy LO, et al. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas. 2000;21(3):310-320.